JUL 16, 2020 10:00 AM PDT

Implications of Rapid IDH1/IDH2 Testing for Liquid and Solid Tumors

Speaker
  • Clinical Development - Molecular Pathology lab at HUP
    Biography
      Sarah Herlihy, Ph.D. received her doctoral degree from Texas A&M University in 2014. She completed her post-doctoral studies at The Wistar Institute in Philadelphia before joining the Division of Precision and Computational Diagnostics at the Hospital of the University of Pennsylvania (HUP). Sarah has over 10 years of experience in academic and clinical oncology research. In her current role as part of the clinical development team in the Molecular Pathology lab at HUP, Sarah designs and validates oncology, infectious disease, and genetic tests to prepare them for clinical use.

    Abstract

    DATE: July 16, 2020

    TIME:  10:00 am PDT

     

    This seminar reviews clinical utility of adopting rapid IDH1/2 testing in both hematological and solid tumors and describes the adjusted workflow developed. Isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are enzymes involved in cellular metabolism and cellular differentiation. Mutations in the IDH1 and IDH2 genes alter their enzymatic activity to produce an oncometabolite. Disease-associated variants in IDH1/2 have clinical implications for multiple forms of cancer. Molecular detection of IDH1 and IDH2 disease-associated variants aids in diagnosis, prognostic stratification, and treatment decisions. For example, detection of IDH variants in acute myeloid leukemia (AML) allows for the addition of IDH-targeted therapies to treatment regimens. Additionally, the diagnosis and prognosis of gliomas are dependent on the IDH1/2 molecular status. In these ways, it is increasingly important to have rapid molecular testing for IDH1/2. Challenges of implementing IDH testing include redundant testing (immunohistochemistry and massively parallel sequencing) and limited specimen material. In order to address these challenges, the clinical utility of rapid IDH1/2 testing was evaluated and modifications to the laboratory workflow were explored. These studies highlight the value of rapid IDH testing and show that procedural adjustments can both streamline laboratory workflows and conserve vital limited specimen material. 

     

    Learning Objectives:

    • Understand the clinical utility of rapid IDH1/2 testing in hematologic neoplasms 
    • Recognize how rapid molecular IDH1/2 testing can aid in the diagnosis of solid tumors 
    • Identify workflow modifications that allow for efficient use of specimens 

     

     

    Webinars will be available for unlimited on-demand viewing after live event.

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
    Loading Comments...
    Show Resources
    Attendees
    • See more